All Stories

  1. A PFAS-steroid axis is associated with lipid and bile acid metabolism in MASLD
  2. Distinct effects of ketogenic and non-ketogenic weight-loss diets on hepatic steatosis and mitochondrial metabolism in MASLD
  3. Hepatic insulin resistance is the basis of bile acid dysmetabolism in metabolic dysfunction-associated steatotic liver disease
  4. Genome-wide interaction study with body mass index identifies <i>CYP7A1</i> and <i>GIPR</i> as genetic modulators of metabolic dysfunction-associated steatotic liver disease
  5. A metabolome-derived score predicts metabolic dysfunction-associated steatohepatitis and mortality from liver disease
  6. Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease
  7. Surveillance of the liver in type 2 diabetes: important but unfeasible?
  8. Corrigendum to “SIRT5 rs12216101 T>G variant is associated with liver damage and mitochondrial dysfunction in patients with non-alcoholic fatty liver disease” [J Hepatol 80 (2024) 10-19]
  9. IL32 downregulation lowers triglycerides and type I collagen in di-lineage human primary liver organoids
  10. Marked difference in liver fat measured by histology vs. magnetic resonance-proton density fat fraction: A meta-analysis
  11. SIRT5 rs12216101 T>G variant is associated with liver damage and mitochondrial dysfunction in patients with non-alcoholic fatty liver disease
  12. The first human normative ranges and biomarker performance of dimethylguanidino valeric acid isoforms in fatty liver disease
  13. Validation of the Blood Test MACK-3 for the Noninvasive Diagnosis of Fibrotic Nonalcoholic Steatohepatitis: An International Study With 1924 Patients
  14. Development and Validation of a Score for Fibrotic Nonalcoholic Steatohepatitis
  15. Programmed cell death 1 genetic variant and liver damage in nonalcoholic fatty liver disease
  16. The quest for the missing links in fatty liver genetics: Deep learning to the rescue!
  17. The human liver lipidome is significantly related to the lipid composition and aggregation susceptibility of low-density lipoprotein (LDL) particles
  18. Higher serum infliximab concentrations during induction predict short-term endoscopic response in patients with inflammatory bowel disease
  19. Heterogeneity of phosphatidylcholine metabolism in non-alcoholic fatty liver disease
  20. Hepatic insulin resistance is the basis of bile acid dysmetabolism in non-alcoholic fatty liver disease
  21. Marked underestimation of liver fat content as measured by magnetic resonance versus histology—a systematic review and meta-analysis
  22. Insulin-inducible THRSP maintains mitochondrial function and regulates sphingolipid metabolism in human adipocytes
  23. Can dysplasia surveillance be better targeted in ulcerative colitis by using faecal calprotectin?
  24. In vitro Effects of Bacterial Exposure on Secretion of Zonulin Family Peptides and Their Detection in Human Tissue Samples
  25. Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease
  26. Exposure to environmental contaminants is associated with altered hepatic lipid metabolism in non-alcoholic fatty liver disease
  27. Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease
  28. Overfeeding Saturated Fat Increases LDL (Low-Density Lipoprotein) Aggregation Susceptibility While Overfeeding Unsaturated Fat Decreases Proteoglycan-Binding of Lipoproteins
  29. Parallel Sessions
  30. Assessment of Lifestyle Factors Helps to Identify Liver Fibrosis Due to Non-Alcoholic Fatty Liver Disease in Obesity
  31. The PNPLA3-I148M Variant Confers an Antiatherogenic Lipid Profile in Insulin-resistant Patients
  32. The PNPLA3‐I148M variant increases polyunsaturated triglycerides in human adipose tissue
  33. Case reports of two pedigrees with recessive arrhythmogenic right ventricular cardiomyopathy associated with homozygous Thr335Ala variant in DSG2